Adverse events · adult patients after liver transplantation.
It is very uncertain whether synbiotics changes adverse events compared with prebiotics (very low certainty).
1 finding from 1 review
Serious adverse events · adult patients after liver transplantation.
It is very uncertain whether synbiotics changes serious adverse events compared with prebiotics (very low certainty).
1 finding from 1 review
Death · adult patients after liver transplantation.
1 finding from 1 review
Graft health · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · adult kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diarrhoea lasting ≥ 48 hours · children and adults with acute infectious diarrhoea
The intervention showed no clear difference in diarrhoea lasting ≥ 48 hours (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean duration of diarrhoea (hours) · children and adults with acute infectious diarrhoea
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Incidence of AAD · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention probably leads to lower incidence of AAD (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
The intervention showed no clear difference in adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Duration of diarrhea (days) · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review
Intervention not reported
Microbiome characteristics · Children receiving antibiotic treatment between 4 and 28 days duration for a variety of infections
1 finding from 1 review
Proportion of children with AOM (overall) · children up to age 18 years
Probiotic probably leads to lower proportion of children with AOM (overall) compared with placebo (moderate certainty).
1 finding from 1 review